Physician profile
Mark Ginkel
NPI 1649272766
$7,608.88
in general payments reported to CMS, 2019-2025
29 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,074 · 2020: $711 · 2021: $1,264 · 2022: $1,328 · 2023: $1,223 · 2024: $1,080 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,233.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biosense Webster, INC. | $1,805.03 | 2019-2025 | Carto 3, Qdot Micro Catheter, Nuvision Ice Catheter |
| Amgen INC. | $1,190.21 | 2019-2024 | Repatha |
| Pfizer INC. | $632.02 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $486.28 | 2019-2023 | Lifevest |
| Novartis Pharmaceuticals Corporation | $471.43 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $455.26 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $447.68 | 2021-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $446.29 | 2021-2025 | Perclose Prostyle, Diamondback Coronary, Aveir |
| Medtronic, INC. | $303.21 | 2021-2025 | Reveal Linq, Micra, Onyx Frontier |
| Astrazeneca Pharmaceuticals Lp | $297.02 | 2019-2024 | Farxiga, Wainua |
| Boston Scientific Corporation | $250.51 | 2019-2023 | |
| Abiomed | $179.01 | 2021-2023 | Impella |
| E.R. Squibb & Sons, L.L.C. | $114.62 | 2019-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.69 | 2020-2021 | |
| Edwards Lifesciences Corporation | $59.98 | 2024-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $51.79 | 2020 | |
| Cardiovascular Systems INC. | $50.13 | 2019-2022 | |
| Esperion Therapeutics, INC. | $44.78 | 2024-2025 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $35.89 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $31.64 | 2019 | |
| Preventice Services, LLC | $29.15 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $28.40 | 2024 | |
| Becton, Dickinson and Company | $20.31 | 2025 | True Flow |
| Amarin Pharma, INC. | $18.03 | 2020 | |
| Cardiva Medical, INC. | $16.69 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Tactile Systems Technology INC | $16.04 | 2019 | |
| Asahi Intecc USA, INC. | $13.65 | 2020 | |
| Philips North America LLC | $12.13 | 2021 | |
| Getinge USA Sales, LLC | $12.01 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Ginkel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.